The Grayson Lab focuses on craniofacial and orthopaedic tissue engineering. Our research addresses the challenges associated with spatio-temporal control of stem cell fate in order to engineer complex tissue constructs. We are developing innovative methods to guide stem cell differentiation patterns and create patient-specific grafts with functional biological and mechanical characteristics. We employ engineering techniques to accurately control growth factor delivery to cells in biomaterial scaffolds as well as to design advanced bioreactors capable of maintaining cell viability in large tissue constructs. These technologies are used to enable precise control of the cellular microenvironment and uniquely address fundamental questions regarding the application of biophysical cues to regulate stem cell differentiation.

Research in the Vestibular NeuroEngineering Lab (VNEL) focuses on restoring inner ear function through “bionic” electrical stimulation, inner ear gene therapy, and enhancing the central nervous system’s ability to learn ways to use sensory input from a damaged inner ear. VNEL research involves basic and applied neurophysiology, biomedical engineering, clinical investigation and population-based epidemiologic studies. We employ techniques including single-unit electrophysiologic recording; histologic examination; 3-D video-oculography and magnetic scleral search coil measurements of eye movements; microCT; micro MRI; and finite element analysis. Our research subjects include computer models, circuits, animals and humans. For more information about VNEL, click here. VNEL is currently recruiting subjects for two first-in-human clinical trials: 1) The MVI Multichannel Vestibular Implant Trial involves implantation of a “bionic” inner ear stimulator intended to partially restore sensation of head movement. Without that sensation, the brain’s image- and posture-stabilizing reflexes fail, so affected individuals suffer difficulty with blurry vision, unsteady walking, chronic dizziness, mental fogginess and a high risk of falling. Based on designs developed and tested successfully in animals over the past the past 15 years at VNEL, the system used in this trial is very similar to a cochlear implant (in fact, future versions could include cochlear electrodes for use in patients who also have hearing loss). Instead of a microphone and cochlear electrodes, it uses gyroscopes to sense head movement, and its electrodes are implanted in the vestibular labyrinth. For more information on the MVI trial, click here. 2) The CGF166 Inner Ear Gene Therapy Trial involves inner ear injection of a genetically engineered DNA sequence intended to restore hearing and balance sensation by creating new sensory cells (called “hair cells”). Performed at VNEL with the support of Novartis and through a collaboration with the University of Kansas and Columbia University, this is the world’s first trial of inner ear gene therapy in human subjects. Individuals with severe or profound hearing loss in both ears are invited to participate. For more information on the CGF166 trial, click here.

The mission and interest of the neuroengineering and Biomedical Instrumentation Lab is to develop novel instrumentation and technologies to study the brain at several levels--from single cell to the whole brain--with the goal of translating the work into practical research and clinical applications. Our personnel include diverse, independent-minded and entrepreneurial students, post docs, and research faculty who base their research on modern microfabrication, stem cell biology, electrophysiology, signal processing, image processing, and integrated circuit design technologies.

Our laboratory pioneers innovations at the intersection of precision neurology, neuroengineering, artificial intelligence, and data science. We develop advanced neural-AI interfaces, autonomous wearable neurotechnologies, and immersive augmented and virtual reality platforms incorporating novel multimodal neuron-sensing technologies designed to personalize diagnostics, enhance therapeutic interventions, and optimize neurological rehabilitation. Leveraging computational neuroscience, AI, and applied data science, we generate robust digital biomarkers to monitor and treat neurologic diseases in real-time. Through interdisciplinary collaborations, we aim to transform clinical practice by providing precise, interactive, and personalized neurologic care that dramatically improves patient outcomes.

The Cardiology Bioengineering Laboratory, located in the Johns Hopkins Hospital, focuses on the applications of advanced imaging techniques for arrhythmia management. The primary limitation of current fluoroscopy-guided techniques for ablation of cardiac arrhythmia is the inability to visualize soft tissues and 3-dimensional anatomic relationships. Implementation of alternative advanced modalities has the potential to improve complex ablation procedures by guiding catheter placement, visualizing abnormal scar tissue, reducing procedural time devoted to mapping, and eliminating patient and operator exposure to radiation. Active projects include • Physiological differences between isolated hearts in ventricular fibrillation and pulseless electrical activity • Successful ablation sites in ischemic ventricular tachycardia in a porcine model and the correlation to magnetic resonance imaging (MRI) • MRI-guided radiofrequency ablation of canine atrial fibrillation, and diagnosis and intervention for arrhythmias • Physiological and metabolic effects of interruptions in chest compressions during cardiopulmonary resuscitation Henry Halperin, MD, is co-director of the Johns Hopkins Imaging Institute of Excellence and a professor of medicine, radiology and biomedical engineering. Menekhem M. Zviman, PhD is the laboratory manager.

The Center for Bioengineering Innovation and Design educates and develops the next generation of leaders in health care technology innovation. CBID creates and develops solutions for major challenges to human health around the world. Our key measure of success is the positive impact of our students and their solutions on the quality and accessibility of health care worldwide.

We are continually in motion. This self-motion is sensed by the vestibular system, which contributes to an impressive range of brain functions, from the most automatic reflexes to spatial perception and motor coordination. The objective of Dr. Cullen's lab's research program is to understand the mechanisms by which self-motion (vestibular) information is encoded and then integrated with signals from other modalities to ensure accurate perception and control of gaze and posture. Our studies investigate the sensorimotor transformations required for the control of movement, by tracing the coding of vestibular stimuli from peripheral afferents, to behaviorally-contingent responses in central pathways, to the readout of accurate perception and behavior. Our experimental approach is multidisciplinary and includes a combination of behavioral, neurophysiological and computational approaches in alert behaving non-human primates and mice. Funding for the laboratory has been and is provided by the Canadian Institutes for Health Research (CIHR), The National Institutes of Health (NIH), the National Sciences and Engineering Research Council of Canada (NSERC), FQRNT / FQRSC (Quebec).

The Kunisaki lab is a NIH-funded regenerative medicine group within the Division of General Pediatric Surgery at Johns Hopkins that works at the interface of stem cells, mechanobiology, and materials science. We seek to understand how biomaterials and mechanical forces affect developing tissues relevant to pediatric surgical disorders. To accomplish these aims, we take a developmental biology approach using induced pluripotent stem cells and other progenitor cell populations to understand the cellular and molecular mechanisms by which fetal organs develop in disease.

Our lab projects can be broadly divided into three major areas: 1) fetal spinal cord regeneration 2) fetal lung development 3) esophageal regeneration

Lab members: Juan Biancotti, PhD (Instructor/lab manager); Annie Sescleifer, MD (postdoc surgical resident); Kyra Halbert-Elliott (med student), Ciaran Bubb (undergrad)

Recent publications:
Kunisaki SM, Jiang G, Biancotti JC, Ho KKY, Dye BR, Liu AP, Spence JR. Human induced pluripotent stem cell-derived lung organoids in an ex vivo model of congenital diaphragmatic hernia fetal lung. Stem Cells Translational Medicine 2021, PMID: 32949227

Biancotti JC, Walker KA, Jiang G, Di Bernardo J, Shea LD, Kunisaki SM. Hydrogel and neural progenitor cell delivery supports organotypic fetal spinal cord development in an ex vivo model of prenatal spina bifida repair. Journal of Tissue Engineering 2020, PMID: 32782773.

Kunisaki SM. Amniotic fluid stem cells for the treatment of surgical disorders in the fetus and neonate. Stem Cells Translational Medicine 2018, 7:767-773

Dr. Fridman's research group invents and develops bioelectronics for Neuroengineering and Medical Instrumentation applications. We develop innovative medical technology and we also conduct the necessary biological studies to understand how the technology could be effective and safe for people. Our lab is currently focused on developing the ""Safe Direct Current Stimulation"" technology, or SDCS. Unlike the currently available commercial neural prosthetic devices, such as cochlear implants, pacemakers, or Parkinson's deep brain stimulators that can only excite neurons, SDCS can excite, inhibit, and even sensitize them to input. This new technology opens a door to a wide range of applications that we are currently exploring along with device development: e.g. peripheral nerve stimulation for suppressing neuropathic pain, vestibular nerve stimulation to correct balance disorders, vagal nerve stimulation to suppress an asthma attack, and a host of other neuroprosthetic applications. Medical Instrumentation MouthLab is a ""tricorder"" device that we invented here in the Machine Biointerface Lab. The device currently obtains all vital signs within 60s: Pulse rate, breathing rate, temperature, blood pressure, blood oxygen saturation, electrocardiogram, and FEV1 (lung function) measurement. Because the device is in the mouth, it has access to saliva and to breath and we are focused now on expanding its capability to obtaining measures of dehydration and biomarkers that could be indicative of a wide range of internal disorders ranging from stress to kidney failure and even lung cancer.

The RISE Lab’s research focuses on developing and evaluating cellular/molecular imaging biosensors and drug/nanoparticle delivery systems for improved therapeutic indices in precision medicine.